Trial Profile

Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RPT 904 (Primary)
Indications Food hypersensitivity
Focus Therapeutic Use
Sponsors RAPT Therapeutics

Most Recent Events

24 Oct 2025 Status changed from planning to not yet recruiting.
07 Aug 2025 According to a RAPT Therapeutics media release, company remain on track to initiate our Phase 2b trial of RPT904 in food allergy later this year.
15 Apr 2025 According to RAPT Therapeutics media release, Brian Wong will be instrumental in advancing RPT904 to a Phase 2b clinical trial for food allergy in the second half of 2025 and generating important data to differentiate RPT904 as an attractive therapeutic option for patients.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com